What I've Learned Writing 100 Articles About Nicotine

One hundred articles. Each one a deep dive into a different corner of the nicotine landscape—the science of addiction, the economics of tobacco, the politics of regulation, the psychology of smokers, the ethics of harm reduction. I've written about e-cigarettes and cigarettes, nicotine pouches and nicotine patches, flavor bans and tax policy, youth epidemics and cessation strategies, the industry's deceptions and public health's blind spots. I've tried, in every piece, to do something that's harder than it sounds: follow the evidence where it leads, acknowledge uncertainty where it exists, and resist the gravitational pull of the two dominant narratives—'nicotine is evil' on one side, 'nicotine is no big deal' on the other. Here's what I've learned.

First, and most important: the delivery system matters more than the molecule. This is the single most important scientific fact in the entire nicotine landscape, and it's the one that's most consistently obscured by both sides of the debate. Nicotine is addictive and not benign, but the vast majority of tobacco-related death and disease is caused not by nicotine but by the products of combustion—the tars, carbon monoxide, and carcinogens produced when tobacco is burned. Separating nicotine from smoke reduces harm by an estimated 90–95%. This fact is supported by decades of toxicology, biomarker studies, and epidemiological evidence from populations (like Swedish snus users) who've used non-combustible nicotine products for generations. Acknowledging it does not mean endorsing nicotine use or minimizing addiction. It means being honest about what actually kills smokers, so that policies can target the thing that kills them rather than the thing that keeps them using the thing that kills them.

Second: the population matters more than the product. The same e-cigarette that helps a 50-year-old smoker quit poses a net harm to a 15-year-old who would never have smoked. The policy challenge is not to determine whether vaping is 'good' or 'bad' in the abstract—it will always be both, depending on who's using it. The challenge is to design regulatory frameworks that maximize the benefit for the population that stands to gain (current smokers) while minimizing the harm to the population that stands to lose (potential never-smokers, particularly youth). This is harder than binary policies—permit or ban, tax or don't—but it's the only approach that's consistent with the evidence. Policies that optimize for one population at the expense of the other will inevitably produce unintended consequences—adult smokers driven back to cigarettes by vaping restrictions, or youth initiated into nicotine by permissive policies. The balance is difficult and the evidence is incomplete, but the difficulty is not an excuse for simplicity. Complex problems require complex solutions.

Third: the institutions matter as much as the evidence. The reason the nicotine debate remains unresolved despite decades of research is not primarily a failure of science. It's a failure of the institutions that interpret and apply the science. The WHO, the FDA, the tobacco industry, the vaping industry, the public health advocacy organizations—each approaches the evidence with institutional interests, funding constraints, and cultural assumptions that shape what evidence is sought, what evidence is credited, and what evidence is dismissed. Understanding the institutional dynamics is essential to understanding why the debate looks the way it does, and why more evidence alone won't resolve it. The path to better policy runs not just through better science but through institutional reform—funding structures that don't penalize harm-reduction research, regulatory frameworks that evaluate products based on risk rather than source, and public health organizations that can acknowledge uncertainty without fearing that it will be weaponized by the industry.

Fourth: the stigma is part of the problem. Smoking has been successfully denormalized—a genuine public health achievement—but the denormalization has shaded into stigmatization in ways that are counterproductive. Smokers who feel judged, shamed, and excluded by the very public health campaigns designed to help them are less likely to engage with cessation services, less likely to be honest with healthcare providers, and more likely to view public health as an adversary rather than an ally. The smokers who remain are disproportionately poor, mentally ill, traumatized, and marginalized—populations for whom smoking is not a 'lifestyle choice' but a coping mechanism for conditions that public health has been slow to address. Reaching these smokers requires rebuilding trust—treating them as partners in their own health improvement, acknowledging the functions that smoking serves in their lives, and offering pathways to reduced harm that feel achievable, not aspirational. The stick of stigma has gotten tobacco control far. The remaining smokers need a hand.

Fifth, and most hopeful: the tools exist to dramatically reduce tobacco-related mortality. The combination of MPOWER measures (taxation, advertising bans, smoke-free laws, health warnings, cessation support), harm reduction (making non-combustible nicotine products accessible, affordable, and appealing to smokers who can't or won't quit nicotine), and structural interventions (addressing poverty, mental health, and the social determinants that drive smoking) could reduce global smoking prevalence to near zero within a generation. The tools are not speculative. They're evidence-based, cost-effective, and in many cases already implemented in countries that have demonstrated their effectiveness. What's missing is not the tools. It's the political will to deploy them at scale, the institutional flexibility to adapt them to a changing product landscape, and the moral imagination to apply them with compassion rather than judgment.

One hundred articles later, I'm more convinced than when I started that the nicotine landscape is more complex, more interesting, and more hopeful than the dominant narratives suggest. The war on tobacco is winnable. Not through prohibition—that's been tried with every addictive substance in human history and failed every time. Not through surrender to the industry—that would be a betrayal of the millions who've died from its products. But through a combination of evidence-based regulation, honest risk communication, accessible cessation support, and harm reduction that meets smokers where they are rather than demanding they become something they're not. The path is narrow, contested, and inadequately mapped. But it exists. And every day, smokers who were told they could never quit are finding it. That's not a reason for complacency. It's a reason for hope.